Ongoing treatment(s)-Chemotherapy Posts on Medivizor
Navigation Menu

Ongoing treatment(s)-Chemotherapy Posts on Medivizor

Evaluating eribulin versus other treatment options in women with advanced breast cancer.

Evaluating eribulin versus other treatment options in women with advanced breast cancer.

Posted by on Aug 29, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the safety and effectiveness between eribulin (Halaven) and non-eribulin-based chemotherapy regimens in patients with advanced breast cancer (BC). The data showed that eribulin significantly improved survival outcomes with manageable side effects in these patients. Some background Advanced BC has spread...

Read More

Evaluating the safety and effectiveness of nimotuzumab combined with chemoradiotherapy for patients with squamous cell lung cancer.

Evaluating the safety and effectiveness of nimotuzumab combined with chemoradiotherapy for patients with squamous cell lung cancer.

Posted by on Aug 22, 2021 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety outcomes of nimotuzumab (Theraloc) combined with chemoradiotherapy (CRT) for the treatment of patients with locally advanced squamous non-small cell lung cancer (SqNSCLC). The data showed that nimotuzumab plus CRT had similar survival outcomes compared to CRT alone, but with a lower...

Read More

Comparing outcomes of donors for a second allogenic stem cell transplant for patients with acute lymphoblastic leukemia

Comparing outcomes of donors for a second allogenic stem cell transplant for patients with acute lymphoblastic leukemia

Posted by on Jul 25, 2021 in Leukemia | 0 comments

In a nutshell This study aimed to compare outcomes of donor types for a second allogeneic stem cell transplant (alloSCT) in patients with relapsed acute lymphoblastic leukemia (ALL).  This study concluded that there is no major difference in overall survival between a matched unrelated donor (MUD) and a half-matched donor (HMD) in...

Read More

Can reducing chemotherapy duration from 6 to 3 months reduce side effects in patients with colorectal cancer and still be effective?

Can reducing chemotherapy duration from 6 to 3 months reduce side effects in patients with colorectal cancer and still be effective?

Posted by on Mar 6, 2021 in Colorectal cancer | 0 comments

In a nutshell This study investigated if reducing therapy duration could reduce side effects in patients but still be effective in patients with stage II colorectal cancer (CRC). This study showed that in certain patients a 3-month treatment duration can be considered.  Some background Patients with colorectal cancer (CRC) can be treated...

Read More

Is nab-paclitaxel a better option than standard solvent-based taxanes for women with breast cancer?

Is nab-paclitaxel a better option than standard solvent-based taxanes for women with breast cancer?

Posted by on Feb 28, 2021 in Breast cancer | 0 comments

In a nutshell This study explored whether nanoparticle albumin-bound (nab) paclitaxel (Abraxane) is more efficient as chemotherapy before surgery compared to solvent-based (sb) taxanes in patients with breast cancer. The authors found that nab-paclitaxel was able to improve the outcomes of these patients. Some background Breast cancer...

Read More

Can a healthy diet improve quality of life of women with breast cancer undergoing chemotherapy?

Can a healthy diet improve quality of life of women with breast cancer undergoing chemotherapy?

Posted by on Feb 28, 2021 in Breast cancer | 0 comments

In a nutshell This study examined whether a healthy diet can improve the quality of life of women with breast cancer undergoing chemotherapy. The authors found that women who followed healthy dietary advice had an improvement in the quality of their life during chemotherapy, reducing nausea, vomiting, and increasing appetite.  Some background...

Read More

How long should patients with locally advanced rectal cancer wait between chemoradiotherapy and surgery to achieve the best outcome?

How long should patients with locally advanced rectal cancer wait between chemoradiotherapy and surgery to achieve the best outcome?

Posted by on Feb 26, 2021 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the timing between chemoradiotherapy (CRT) and surgery in patients with locally advanced rectal cancer (LARC). The study found that patients who had surgery more than 10 weeks after CRT had the best outcome. Some background Rectal cancer is commonly treated with surgery to remove the tumor. LARC is...

Read More

Can a nanoparticle-based paclitaxel be more effective than a standard-preparation paclitaxel in the treatment of advanced non-small cell lung cancer?

Can a nanoparticle-based paclitaxel be more effective than a standard-preparation paclitaxel in the treatment of advanced non-small cell lung cancer?

Posted by on Jan 19, 2021 in Lung cancer | 0 comments

In a nutshell This trial compared the use of standard paclitaxel (SP; Taxol) versus a new nanoparticle micellar preparation of paclitaxel (NmP) as a first-line treatment for non-small cell lung cancer (NSCLC). The authors found that NmP had better effectiveness and safety in treating NSCLC than SP.  Some...

Read More

The effect of chemotherapy dose intensity on outcomes for patients with aggressive adult T-cell leukemia/lymphoma

The effect of chemotherapy dose intensity on outcomes for patients with aggressive adult T-cell leukemia/lymphoma

Posted by on Jan 4, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study aimed to investigate the effect of chemotherapy dose intensity on outcomes for patients with adult T-cell leukemia/lymphoma.  This study concluded that higher chemotherapy dose intensity improves outcomes for these patients.  Some background Adult T-cell leukemia/lymphoma (ATL) is an aggressive blood cancer. It can...

Read More

Pembrolizumab plus chemotherapy can delay progression of advanced triple negative breast cancer

Pembrolizumab plus chemotherapy can delay progression of advanced triple negative breast cancer

Posted by on Dec 31, 2020 in Breast cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety of pembrolizumab (Keytruda) plus chemotherapy in patients with inoperable or metastatic triple-negative breast cancer. The data showed that the combination is effective in improving progression-free survival in these patients. Some background Triple-negative breast cancer (TNBC)...

Read More

Cetuximab combined with irinotecan improves the outcomes of patients with advanced colorectal cancer

Cetuximab combined with irinotecan improves the outcomes of patients with advanced colorectal cancer

Posted by on Dec 20, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of irinotecan (Camptosar) with and without cetuximab (Erbitux) in the treatment of metastatic (spread to other parts of the body) colorectal cancer (mCRC). Researchers suggested that combined treatment improves the outcomes of these patients. Some background Colorectal cancer (CRC) is one of...

Read More